Navigation Links
CuraGen Announces Top-Line Phase II Results on Velafermin
Date:10/11/2007

n

Combination with Carboplatin and Paclitaxel (BelCaP) for

Patients (pts) with Relapsed Ovarian Cancer

Date: Thursday, October 25, 2007

Poster Board: C223

Session: Poster Session C: Other Small Molecule Therapeutic Agents

Title: A Phase I Study of Oral Belinostat (PXD101) in Patients

with Advanced Solid Tumors

Date: Wednesday, October 24, 2007

Poster Board: B134

Session: Poster Session B: Epigenetic Targets

Title: A Phase 1 Study of Belinostat (PXD101) in Combination with

Bortezomib in Patients with Advanced Solid Tumors and

Lymphoma

Date: Tuesday, October 23, 2007

Poster Board: A149

Session: Poster Session A: Clinical Trials

Title: A Phase II Trial of the Histone Deacetylase Inhibitor

Belinostat (PXD101) in Patients with Platinum Resistant

Epithelial Ovarian Tumors and Micropapillary/Borderline

(LMP) Ovarian Tumors. A Trial of the PMH Phase II

Consortium

Date: Tuesday, October 23, 2007

Poster Board: A160

Session: Poster Session A: Clinical Trials

CR011-vcMMAE

Title: A Phase I and Pharmacokinetic Study of CR011-vcMMAE, an

Antibody Toxin Conjugate Drug, in Patients with

Unresectable Stage III /IV Melanoma

Date: Wednesday, October 24, 2007

Poster Board: B47

Session: Poster Session B: Biological Therapeutic Agents

Title: Pharmacologically Enhanced Expression of the

Melanoma-Associated Target, GPNMB, Increases the

Sensitivity of Melanoma Cells to the CR011-vcMMAE

Antibody-Drug Conjugate

Date:
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Coast Dental Deploys Demandforce D3 Communications Platform 56970 1Coast Dental Deploys Demandforce D3 Communications Platform 56970 2Swine Flu Trials Continue to Point to 1 Dose Vaccine 56966 1Swine Flu Trials Continue to Point to 1 Dose Vaccine 56966 2Swine Flu Trials Continue to Point to 1 Dose Vaccine 56966 3Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea 4976 1Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea 4976 2